Literature DB >> 10906225

Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

V Molinier-Frenkel1, H Gahery-Segard, M Mehtali, C Le Boulaire, S Ribault, P Boulanger, T Tursz, J G Guillet, F Farace.   

Abstract

We previously demonstrated that a single injection of 10(9) PFU of recombinant adenovirus into patients induces strong vector-specific immune responses (H. Gahéry-Ségard, V. Molinier-Frenkel, C. Le Boulaire, P. Saulnier, P. Opolon, R. Lengagne, E. Gautier, A. Le Cesne, L. Zitvogel, A. Venet, C. Schatz, M. Courtney, T. Le Chevalier, T. Tursz, J.-G. Guillet, and F. Farace, J. Clin. Investig. 100:2218-2226, 1997). In the present study we analyzed the mechanism of vector recognition by cytotoxic T lymphocytes (CTL). CD8(+) CTL lines were derived from two patients and maintained in long-term cultures. Target cell infections with E1-deleted and E1-plus E2-deleted adenoviruses, as well as transcription-blocking experiments with actinomycin D, revealed that host T-cell recognition did not require viral gene transcription. Target cells treated with brefeldin A were not lysed, indicating that viral input protein-derived peptides are associated with HLA class I molecules. Using recombinant capsid component-loaded targets, we observed that the three major proteins could be recognized. These results raise the question of the use of multideleted adenoviruses for gene therapy in the quest to diminish antivector CTL responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906225      PMCID: PMC112292          DOI: 10.1128/jvi.74.16.7678-7682.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.

Authors:  R G Crystal; N G McElvaney; M A Rosenfeld; C S Chu; A Mastrangeli; J G Hay; S L Brody; H A Jaffe; N T Eissa; C Danel
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

2.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.

Authors:  M Lusky; L Grave; A Dieterlé; D Dreyer; M Christ; C Ziller; P Furstenberger; J Kintz; D A Hadji; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

Authors:  S R Riddell; M Rabin; A P Geballe; W J Britt; P D Greenberg
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

6.  Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.

Authors:  J Zabner; L A Couture; R J Gregory; S M Graham; A E Smith; M J Welsh
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

7.  Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

Authors:  Y Yang; G Trinchieri; J M Wilson
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

8.  Cells process exogenous proteins for recognition by cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; Y Hosaka
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

9.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

10.  Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

Authors:  S K Tripathy; H B Black; E Goldwasser; J M Leiden
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  30 in total

1.  Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types.

Authors:  Clare E Thomas; Penny Edwards; Thomas J Wickham; Maria G Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

4.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.

Authors:  G Yin; J Chen; S Wei; H Wang; Q Chen; Y Lin; J Hu; E Luo
Journal:  Gene Ther       Date:  2015-04-14       Impact factor: 5.250

Review 6.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

7.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 8.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

9.  Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.

Authors:  M Puntel; R J Barrett; S Mondkar; V Saxena; K M Kroeger; A K M Muhammad; C Liu; N Bondale; S Sciascia; W Xiong; Y Shi; A Salem; A Zadmehr; P Huynh; D Palmer; P Ng; M G Castro; P R Lowenstein
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 10.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.